Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician

Area of Science:

• Oncology
• Clinical Trial Design
• Biostatistics

Background:

• Modern cancer drug development increasingly utilizes molecularly targeted agents, immunotherapies, and radiotherapy.
• These novel agents possess diverse mechanisms of action and administration schedules, leading to unique toxicity profiles.
• Traditional dose-finding designs, such as the 3+3 design, face significant challenges with these new agents, particularly concerning combinations and late-onset toxicities.

Purpose of the Study:

• To provide essential guidelines for the early design stages of dose-finding clinical trials involving novel anticancer agents.
• To facilitate effective communication and collaboration between clinical and statistical teams.
• To enhance the selection and implementation of appropriate trial designs for new anticancer therapies.

Main Methods:

• Review of challenges in applying traditional designs to novel anticancer agents.
• Identification of key considerations for novel dose-finding trial designs.
• Development of guiding questions for clinical and statistical team interactions.

Main Results:

• Traditional designs are often inadequate for novel anticancer agents due to complex toxicity profiles and administration schedules.
• Novel statistical designs are emerging but require careful consideration of study-specific factors.
• Effective collaboration is crucial for selecting designs that align with study objectives and drug characteristics.

Conclusions:

• Improved dose-finding trial designs are critical for the successful development of novel anticancer agents.
• Early and structured interaction between clinicians and statisticians is paramount.
• Adherence to design guidelines ensures that trial methodologies accurately address the unique properties of new cancer therapies.